NASHTranslation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH By Graviton / 09/2021 NASH and Fibrosis Conference
NASHTVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial By Graviton / 07/2021 Gastroenterology
NASHAnalysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640 By Graviton / 06/2021 EASL International Liver Congress
NASHNovel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH By Graviton / 11/2020 AASLD
NASHNovel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH By Graviton / 08/2020 EASL International Liver Congress
NASHThe FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH By Graviton / 08/2020 EASL International Liver Congress
NASHFatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities By Graviton / 07/2020 Hepatology 2020
NASHFibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent By Graviton / 11/2018 ObesityWeek